Kidney-Liver cancer drug kills CLL cells

[Guest guest]

Sorafenib, a multikinase inhibitor, induces cell death in CLL by translational

downregulation of Mcl-1. Works across stages and CD38 and Zap70 subgroups.

In addition, researchers provide evidence that sorafenib can overcome drug

resistance in CLL cells protected by microenvironmental signals from stromal

cells.

The researchers state:

" Conclusively, sorafenib is highly active in CLL and may compose a new

therapeutic option for patients who relapse after immuno chemotherapy. "

Source:Leukemia

http://www.nature.com/leu/journal/vaop/ncurrent/full/leu20112a.html

Really early days...

~chris